Abstract: Objective To observe the clinical effects of lamivudine and Liuweiwuling tablets on chronic hepatitis B patients with HBeAg-positive. Methods Total of 100 CHB patients with HBeAg-positive were randomly divided into treatment group (50 cases) and control group (50 cases). Treatment group were treated with  lamivudine (100 mg, once daily) combined with Liuweiwuling tablets (2 g, three times a day); control group were treated with lamivudine (100 mg, once daily) combined with liver-protecting tablet (1.4 g, three times a day). Both groups were treated for 24 weeks and then continued with lamivudine. ALT, HBV-M, HBV DNA and serum  liver fibrosis indexes were tested. Results At the end of treatment, 18 cases were excellent and 26 cases were effective in treatment group, with the total effective rate was 88%; 6 cases were excellent and 21 cases were effective in control group, with the total effective rate was 54%. The otal effective rate and serum liver fibrosis indexes of treatment group was better than that in the control group (P ＜ 0.05). Conclusions Lamivudine combined with Liuweiwuling tablets has a positive curative effect on inhibiting hepatitis B virus replication, recovering liver function and treating epatic fibrosis for chronic hepatitis B patients.